Comparison of access ultrasensitive human growth hormone assay to monoclonal antibody-based immunoradiometric assay

2007 ◽  
Vol 376 (1-2) ◽  
pp. 248-249 ◽  
Author(s):  
Kunuhiro Iwahara ◽  
Chizuko Tanabe ◽  
Masato Maekawa
1996 ◽  
Vol 10 (1) ◽  
pp. 49-55 ◽  
Author(s):  
Kazuko Horiuchi ◽  
Lin H. Lin ◽  
Yasuhisa Fujibayashi ◽  
Vania C. Borghi ◽  
Akira Yokoyama

1984 ◽  
Vol 5 (3-4) ◽  
pp. 145-157 ◽  
Author(s):  
Françoise Gomez ◽  
Guy Pirens ◽  
Charles Schaus ◽  
Jean Closset ◽  
Georges Hennen

1993 ◽  
Vol 39 (8) ◽  
pp. 1620-1625 ◽  
Author(s):  
K Albertsson-Wikland ◽  
C Jansson ◽  
S Rosberg ◽  
A Novamo

Abstract We describe a time-resolved immunofluorometric assay (trIFMA) for human growth hormone (hGH), in which monoclonal antibody (mAb)-coated microtiter strip wells and a europium (Eu) chelate-labeled mAb are used. We compare the new trIFMA, in which two mAbs are used, with an immunoradiometric assay (IRMA) in which polyclonal antibodies are used. Serum samples (n = 185) from 36 children with various diagnoses were analyzed. In addition, 24-h profile samples (72 per child) from 39 children were analyzed. The trIFMA was more sensitive (detection limit, 0.03 mIU/L) than existing IRMAs. Both the intra- and interassay CVs were < or = 10.6% for hGH concentrations between 1 and 100 mIU/L. The trIFMA is technically simple and rapid, requires no centrifugation or separation reagent, and has a counting time of only 1 s per sample. In addition, the Eu label is nontoxic, presents no waste-disposal problems, and has a long shelf-life. Finally, the assay requires only small volumes of serum (25 muL), which is of considerable importance in pediatric use. The mAbs used for the trIFMA selectively bind the 22-kDa form of hGH, with the result that the assay detects about 80% of the amount detected by the polyclonal IRMA.


1988 ◽  
Vol 117 (1) ◽  
pp. 85-90 ◽  
Author(s):  
A. T. Holder ◽  
J. A. Blows ◽  
R. Aston ◽  
P. C. Bates

ABSTRACT Dwarf mice were treated for 10 days with phosphate-buffered saline (PBS), human growth hormone (hGH) or hGH with monoclonal antibody EB1 (hGH/MAB-EB1); for each treatment there were three groups which received 50, 75 or 100% of the amount of food eaten when available ad libitum. The PBS control groups lost more or gained less weight than equivalent groups receiving hGH alone, and mice given hGH/MAB-EB1 showed a greater weight gain than those in comparable groups receiving hGH alone. When weight gain or loss was expressed as g/g food eaten, groups treated with hGH gained more or lost less than the PBS groups. Similarly, weight gain/g food was significantly greater in hGH/MAB-EB1 animals than in the comparable groups given hGH alone. A similar pattern of response was observed for increases in tail length and uptake of 35SO42− into costal cartilage in vivo. For mice given hGH alone, fat content was decreased compared with that in the equivalent group given PBS, and mice treated with hGH/MAB-EB1 had less fat than the equivalent group given hGH alone. Administration of hGH alone caused a concomitant increase in protein content and body weight such that, compared with mice given PBS, there was no significant increase in protein as a proportion of body weight. However, hGH/MAB-EB1 caused an increase in whole body protein which was significantly greater than that for the equivalent group given hGH alone, when expressed as per cent body weight. Monoclonal antibody EB1 has been shown to enhance the actions of hGH on growth and body composition in Snell dwarf mice and to increase food conversion efficiency. J. Endocr. (1988) 117,85–90


Life Sciences ◽  
2000 ◽  
Vol 66 (11) ◽  
pp. 1021-1031 ◽  
Author(s):  
Rubén C. Aguilar ◽  
Viviana C. Blank ◽  
Lilia A. Retegui ◽  
Leonor P. Roguin

The Lancet ◽  
1968 ◽  
Vol 292 (7566) ◽  
pp. 492-493 ◽  
Author(s):  
L.E.M. Miles ◽  
C.N. Hales

1992 ◽  
Vol 38 (10) ◽  
pp. 2107-2110 ◽  
Author(s):  
G Banfi ◽  
M Marinelli ◽  
M Pontillo ◽  
P Bonini

Abstract Discrepancies among different methods for assaying human growth hormone have been described in various studies. The two major sources of discordant results are the heterogeneity of the antibodies and the different standardization bases used by the assay manufacturers. We propose standardizing assays with 22-kDa biosynthetic monomer human growth hormone diluted with the diluents supplied by the kit manufacturers. In a study of two monoclonal immunoradiometric assays (Hybritech, specific for the 22-kDa monomer; Sorin, recognizing also a 20-kDa variant hormone), standardization with 22-kDa monomer human growth hormone reduced by 63% the differences in results for 44 serum samples from children. The use of 22-kDa human growth hormone as a common standard, highly pure and easily available in large quantities, could help limit the interpretative problems in growth diagnostics.


1992 ◽  
Vol 38 (4) ◽  
pp. 553-557 ◽  
Author(s):  
P J Pringle ◽  
J Jones ◽  
P C Hindmarsh ◽  
M A Preece ◽  
C G Brook

Abstract The immunoradiometric assay (IRMA) used in our laboratory for the measurement of growth hormone (hGH; somatotropin) performed badly in the national proficiency survey program, the U.K. External Quality Assessment Scheme (EQAS). We compared our assay with another IRMA, which gave similar results for patients' samples and performed adequately in EQAS. The samples from EQAS are collected from patients with polycythemia and fall into two categories: those containing endogenous hGH and those supplemented with pituitary-derived hGH. Analysis of the two groups separately showed that the differences between the two IRMAS were in the measurement of the endogenous hormone. The reason for this appears to be a matrix effect related to the fact that the EQAS serum samples are collected from polycythemic patients.


Sign in / Sign up

Export Citation Format

Share Document